Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2012; 137(48): 2498
DOI: 10.1055/s-0032-1327303
DOI: 10.1055/s-0032-1327303
Pro & Contra | Commentary
Hypertensiologie
Duale RAS-Blockade in der antihypertensiven Therapie – pro
Dual blockade of the renin-angiotensin system in hypertensive treatment: yesFurther Information
Publication History
Publication Date:
20 November 2012 (online)

-
Literatur
- 1 ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362 (17) 1575-1585
- 2 Haller H, Ito S, Izzo Jr JL et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917
- 3 Li NC, Lee A, Whitmer RA et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population. BMJ 2010; 340: b5465
- 4 Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study). Lancet 2008; 372: 547-553
- 5 Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;
- 6 Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559